Browse > Article
http://dx.doi.org/10.3831/KPI.2018.21.026

Neuroprotective Agents in the Intensive Care Unit -Neuroprotective Agents in ICU -  

Panahi, Yunes (Clinical Pharmacy Department, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences)
Mojtahedzadeh, Mojtaba (Research Center for Rational Use of Drugs, Tehran University of Medical Sciences)
Najafi, Atabak (Gastrointestinal Pharmacology Interest Group(GPIG), Universal Scientific Education and Research Network(USERN))
Rajaee, Seyyed Mahdi (Gastrointestinal Pharmacology Interest Group(GPIG), Universal Scientific Education and Research Network(USERN))
Torkaman, Mohammad (Department of Pediatrics, School of Medicine, Baqiyatallah University of Medical Sciences)
Sahebkar, Amirhossein (Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences)
Publication Information
Journal of Pharmacopuncture / v.21, no.4, 2018 , pp. 226-240 More about this Journal
Abstract
Neuroprotection or prevention of neuronal loss is a complicated molecular process that is mediated by various cellular pathways. Use of different pharmacological agents as neuroprotectants has been reported especially in the last decades. These neuroprotective agents act through inhibition of inflammatory processes and apoptosis, attenuation of oxidative stress and reduction of free radicals. Control of this injurious molecular process is essential to the reduction of neuronal injuries and is associated with improved functional outcomes and recovery of the patients admitted to the intensive care unit. This study reviews neuroprotective agents and their mechanisms of action against central nervous system damages.
Keywords
neuroprotection; intensive care unit; stroke;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bharosay A, Bharosay VV, Varma M, Saxena K, Sodani A, Saxena R. Correlation of Brain Biomarker Neuron Specific Enolase (NSE) with Degree of Disability and Neurological Worsening in Cerebrovascular Stroke. Indian J Clin Biochem. 2012;27:186-90.   DOI
2 Gonzalez-Garcia S, Gonzalez-Quevedo A, Fernandez-Concepcion O, Pena-Sanchez M, Menendez-Sainz C, Hernandez-Diaz Z, et al. Short-term prognostic value of serum neuron specific enolase and S100B in acute stroke patients. Clinical Biochemistry, 2012;45:1302-7.   DOI
3 Lee TM, Ivers NM, Bhatia S, Butt DA, Dorian P, et al. Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial. Implementation Science. 2016;11:159.   DOI
4 Lip GYH. Optimizing stroke prevention in elderly patients with atrial fibrillation. Journal of Thrombosis and Haemostasis 2016;14:2121-2123.   DOI
5 Mazurek M, Lip GY. To occlude or not? Left atrial appendage occlusion for stroke prevention in atrial fibrillation. Heart. 2017;103:93-95.   DOI
6 Mizukoshi G, Katsura K-I, Katayama Y. Urinary 8-hydroxy-2'-deoxyguanosine and serum $S100{\beta}$ in acute cardioembolic stroke patients. Neurological Research. 2013;27:644-646.
7 Saver JL, Starkman S, Eckstein M, Stratton SJ, Pratt FD, Hamilton S, et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med. 2015;372:528-36.   DOI
8 Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31:2442-9.   DOI
9 Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001;32:980-6.   DOI
10 Moon GJ, Kim SJ, Cho YH, Ryoo S, Bang OY. Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease. Journal of Clinical Neurology. 2014;10:140.   DOI
11 Montaner J, Chacon P, Krupinski J, Rubio F, Millan M, Molina CA, et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. European Journal of Neurology. 2007;15:82-90.   DOI
12 Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880-5.   DOI
13 Cordenier A, De Smedt A, Brouns R, Uyttenboogaart M, De Raedt S, Luijckx GJ, et al. Pre-stroke use of statins on stroke outcome: a meta-analysis of observational studies. Acta Neurol Belg. 2011;111:261-7.
14 Hong KS, Lee JS. Statins in Acute Ischemic Stroke: A Systematic Review. Journal of Stroke. 2015;17:282-301.   DOI
15 Lelli D, Pedone C, Sahebkar A. Curcumin and treatment of melanoma: The potential role of microRNAs. Biomed Pharmacother. 2017;88:832-834.   DOI
16 Ramezani M, Hatamipour M, Sahebkar A. Promising Anti-tumor properties of Bisdemethoxycurcumin: A Naturally Occurring Curcumin Analogue. J Cell Physiol; 2017.
17 Elbini Dhouib I, Jallouli M, Annabi A, Gharbi N, Elfazaa S, Lasram MM. A minireview on N-acetylcysteine: An old drug with new approaches. Life Sciences. 2016;151:359-363.   DOI
18 Singh H, Jalodia S, Gupta MS, Talapatra P, Gupta V, Singh I. Role of magnesium sulfate in neuroprotection in acute ischemic stroke. Ann Indian Acad Neurol. 2012;15:177-80.   DOI
19 Talkachova A, Jaakkola J, Mustonen P, Kiviniemi T, Hartikainen JEK, Palomaki A, et al. Stroke as the First Manifestation of Atrial Fibrillation. Plos One. 2016;11:e0168010.   DOI
20 Arakawa M, Ito Y. N-acetylcysteine and neurodegenerative diseases: Basic and clinical pharmacology. The Cerebellum. 2007;6:308-314.   DOI
21 Bavarsad Shahripour R, Harrigan MR, Alexandrov AV. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain and Behavior. 2014;4:108-122.   DOI
22 Cuzzocrea S, Mazzon E, Costantino G, Serraino I, Dugo L, Calabro G, et al. Beneficial effects ofn-acetylcysteine on ischaemic brain injury. British Journal of Pharmacology. 2000;130:1219-1226.   DOI
23 Sen O, Caner H, Aydin MV, Ozen O, Atalay B, Altinors N, et al. The effect of mexiletine on the level of lipid peroxidation and apoptosis of endothelium following experimental subarachnoid hemorrhage. Neurol Res. 2006;28:859-63.   DOI
24 Findlay JM, Weir BK, Kanamaru K, Espinosa F. Arterial wall changes in cerebral vasospasm. Neurosurgery. 1989;25:736-45; discussion 745-6.   DOI
25 Chen G, Shi J, Hu Z, Hang C. Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine. Mediators Inflamm. 2008;2008:716458.
26 Teymouri M, Pirro M, Johnston TP, Sahebkar A. Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features. Biofactors; 2016.
27 Momtazi AA, Shahabipour F, Khatibi S, Johnston TP, Pirro M, Sahebkar A. Curcumin as a MicroRNA Regulator in Cancer: A Review. Rev Physiol Biochem Pharmacol. 2016;171:1-38.
28 Momtazi AA, Sahebkar A. Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile. Curr Pharm Des. 2016;22:4386-97.   DOI
29 Rezaee R, Momtazi AA, Monemi A, Sahebkar A. Curcumin: A potentially powerful tool to reverse cisplatin-induced toxicity. Pharmacol Res. 2017;117:218-227.   DOI
30 Mirzaei H, Naseri G, Rezaee R, Mohammadi M, Banikazemi Z, Mirzaei HR, et al. Curcumin: A new candidate for melanoma therapy? Int J Cancer. 2016;139:1683-95.   DOI
31 Sahebkar A, Henrotin Y. Analgesic efficacy and safety of curcuminoids in clinical practice: A systematic review and meta-analysis of randomized controlled trials. Pain Medicine (United States). 2016;17:1192-1202.
32 Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendia LE, Sahebkar A. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. J Cardiovasc Pharmacol. 2016;68:223-9.   DOI
33 Nakka VP, Gusain A, Mehta SL, Raghubir R. Molecular Mechanisms of Apoptosis in Cerebral Ischemia: Multiple Neuroprotective Opportunities. Molecular Neurobiology. 2007;37:7-38.
34 Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D. Antioxidant therapy in acute central nervous system injury: current state. Pharmacological Reviews. 2002;54:271-84.   DOI
35 Chen H, Yoshioka H, Kim GS, Jung JE, Okami N, Sakata H, et al. Oxidative Stress in Ischemic Brain Damage: Mechanisms of Cell Death and Potential Molecular Targets for Neuroprotection. Antioxidants & Redox Signaling. 2011;14:1505-1517.   DOI
36 Navarro-Yepes J, Zavala-Flores L, Anandhan A, Wang F, Skotak M, Chandra N, et al. Antioxidant gene therapy against neuronal cell death. Pharmacology & Therapeutics. 2014;142:206-230.   DOI
37 Guney O, Erdi F, Esen H, Kiyici A, Kocaogullar Y. N-acetylcysteine prevents vasospasm after subarachnoid hemorrhage. World Neurosurg. 2010;73:42-9;discussion e3.   DOI
38 Pereira Filho Nde A, Pereira Filho Ade A, Soares FP, Coutinho LM. Effect of N-acetylcysteine on vasospasm in subarachnoid hemorrhage. Arq Neuropsiquiatr. 2010;68:918-22.   DOI
39 Ali T, Badshah H, Kim TH, Kim MO. Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-KB/JNK signaling pathway in aging mouse model. Journal of Pineal Research. 2015;58:71-85.   DOI
40 Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surgical Neurology. 2006;66:232-245.   DOI
41 Niizuma K, Endo H, Chan PH. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. Journal of Neurochemistry. 2009;109:133-138.   DOI
42 O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 Experimental treatments in acute stroke. Annals of Neurology. 2006;59:467-477.   DOI
43 Danysz W, Parsons CG. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotoxicity Research. 2002;4:119-26.   DOI
44 Schauwecker PE. Neuroprotection by glutamate receptor antagonists against seizure-induced excitotoxic cell death in the aging brain. Experimental Neurology. 2010;224:207-218.   DOI
45 van den Bergh WM, Algra A, van Kooten F, Dirven CM, van Gijn J, Vermeulen M, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2005;36:1011-5.   DOI
46 Milani D, Cross JL, Anderton RS, Blacker DJ, Knuckey NW, Meloni BP. Neuroprotective efficacy of poly-arginine R18 and NA-1 (TAT-NR2B9c) peptides following transient middle cerebral artery occlusion in the rat. Neuroscience Research. 2017;114:9-15.   DOI
47 Akdemir H, Kulakszoglu EO, Tucer B, Menku A, Postalc L, Gunald O. Magnesium Sulfate Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage. Neurosurgery Quarterly. 2009;19:35-39.   DOI
48 Chen T, Carter BS. Role of magnesium sulfate in aneurysmal subarachnoid hemorrhage management: A meta-analysis of controlled clinical trials. Asian J Neurosurg. 2011;6:26-31.   DOI
49 Hassan T, Nassar M, Elhadi SM, Radi WK. Effect of magnesium sulfate therapy on patients with aneurysmal subarachnoid hemorrhage using serum S100B protein as a prognostic marker. Neurosurg Rev. 2012;35:421-7;discussion 427.   DOI
50 Muroi C, Terzic A, Fortunati M, Yonekawa Y, Keller E. Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol. 2008;69:33-9;discussion 39.   DOI
51 Veyna RS, Seyfried D, Burke DG, Zimmerman C, Mlynarek M, Nichols V, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;96:510-4.   DOI
52 Watson N, Diamandis T, Gonzales-Portillo C, Reyes S, Borlongan CV. Melatonin as an Antioxidant for Stroke Neuroprotection. Cell Transplantation. 2016;25:883-891.   DOI
53 Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, et al. Melatonin: Pharmacology, Functions and Therapeutic Benefits. Current Neuropharmacology. 2017;15:434-443.   DOI
54 Rios ER, Venancio ET, Rocha NF, Woods DJ, Vasconcelos S, Macedo D, et al. Melatonin: pharmacological aspects and clinical trends. Int J Neurosci. 2010;120:583-90.   DOI
55 Boutin JA, Audinot V, Ferry G, Delagrange P. Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci. 2005;26:412-9.   DOI
56 Bandyopadhyay D, Biswas K, Bandyopadhyay U, Reiter RJ, Banerjee RK. Melatonin protects against stress-induced gastric lesions by scavenging the hydroxyl radical. J Pineal Res. 2000;29:143-51.   DOI
57 Chahbouni M, Escames G, Venegas C, Sevilla B, Garcia JA, Lopez LC, et al. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. Journal of Pineal Research. 2010;48:282-289.   DOI
58 Pei Z, Fung PC, Cheung RT. Melatonin reduces nitric oxide level during ischemia but not blood-brain barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model. J Pineal Res. 2003;34:110-8.   DOI
59 Koh PO. Melatonin regulates nitric oxide synthase expression in ischemic brain injury. J Vet Med Sci. 2008;70:747-50.   DOI
60 Ganjali S, Blesso CN, Banach M, Pirro M, Majeed M, Sahebkar A. Effects of curcumin on HDL functionality. Pharmacol Res. 2017;119:208-218.   DOI
61 Ayuso MI, Montaner J. Advanced neuroprotection for brain ischemia: an alternative approach to minimize stroke damage. Expert Opinion on Investigational Drugs. 2015;24:1137-1142.   DOI
62 Milani D, Knuckey NW, Anderton RS, Cross JL, Meloni BP. The R18 Polyarginine Peptide Is More Effective Than the TAT-NR2B9c (NA-1) Peptide When Administered 60 Minutes after Permanent Middle Cerebral Artery Occlusion in the Rat. Stroke Research and Treatment. 2016;2016:1-9.
63 Cook DJ, Teves L, Tymianski M. A Translational Paradigm for the Preclinical Evaluation of the Stroke Neuroprotectant Tat-NR2B9c in Gyrencephalic Nonhuman Primates. Science Translational Medicine. 2012;4:154ra133-154ra133.
64 Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, ter-Brugge KG, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): A phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 2012;11:942-950.   DOI
65 Marshall J, Wong KY, Rupasinghe CN, Tiwari R, Zhao X, Berberoglu ED, et al. Inhibition ofN-Methyl-d-aspartate-induced Retinal Neuronal Death by Polyarginine Peptides Is Linked to the Attenuation of Stress-induced Hyperpolarization of the Inner Mitochondrial Membrane Potential. Journal of Biological Chemistry. 2015;290:22030-22048.   DOI
66 Meloni BP, Brookes LM, Clark VW, Cross JL, Edwards AB, Anderton RS, et al. Poly-Arginine and Arginine-Rich Peptides are Neuroprotective in Stroke Models. Journal of Cerebral Blood Flow & Metabolism. 2015;35:993-1004.   DOI
67 Beni SM. Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NF- B and AP-1. The FASEB Journal; 2003.
68 Akca T, Canbaz H, Tataroglu C, Caglikulekci M, Tamer L, Colak T, et al. The Effect of N-Acetylcysteine on Pulmonary Lipid Peroxidation and Tissue Damage. Journal of Surgical Research. 2005;129:38-45.   DOI
69 Westermaier T, Stetter C, Vince GH, Pham M, Tejon JP, Eriskat J, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med. 2010;38:1284-90.   DOI
70 Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, et al. Plasma magnesium concentrations and clinical outcomes in aneurysmal subarachnoid hemorrhage patients: post hoc analysis of intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage trial. Stroke. 2010;41:1841-4.   DOI
71 Frishman WH, Saunders E. beta-Adrenergic blockers. J Clin Hypertens (Greenwich). 2011;13:649-53.   DOI
72 Koch-Weser J, Frishman WH. beta-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981;305:500-6.   DOI
73 Savitz SI, Erhardt JA, Anthony JV, Gupta G, Li X, Barone FC, et al. The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab. 2000;20:1197-204.   DOI
74 Schroeppel TJ, Fischer PE, Zarzaur BL, Magnotti LJ, Clement LP, Fabian TC, et al. Beta-adrenergic blockade and traumatic brain injury: protective? J Trauma. 2010;69:776-82.   DOI
75 Salim A, Hadjizacharia P, Brown C, Inaba K, Teixeira PGR, Chan L, et al. Significance of Troponin Elevation After Severe Traumatic Brain Injury. The Journal of Trauma: Injury, Infection, and Critical Care. 2008;64:46-52.   DOI
76 Zabihi NA, Pirro M, Johnston TP, Sahebkar A. Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr Pharm Des; 2016.
77 Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med. 2014;22:851-7.   DOI
78 Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol. 2014;11:123.
79 Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, et al. Lipid lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel. Archives of Medical Science. 2017;13:965-1005.
80 Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Phytother Res. 2016;30:1540-8.   DOI
81 Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendia LE, Sahebkar A. Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Drug Res (Stuttg); 2017.
82 Zhu HT, Bian C, Yuan JC, Chu WH, Xiang X, Chen F, et al. Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NF-kappaB signaling pathway in experimental traumatic brain injury. J Neuroinflammation. 2014;11:59.   DOI
83 Sun Y, Dai M, Wang Y, Wang W, Sun Q, Yang G-Y, et al. Neuroprotection and Sensorimotor Functional Improvement by Curcumin after Intracerebral Hemorrhage in Mice. Journal of Neurotrauma. 2011;28:2513-2521.   DOI
84 Reiter RJ, Mayo JC, Tan D-X, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. Journal of Pineal Research. 2016;61:253-278.   DOI
85 Ozdemir D, Uysal N, Gonenc S, Acikgoz O, Sonmez A, Topcu A, et al. Effect of melatonin on brain oxidative damage induced by traumatic brain injury in immature rats. Physiol Res. 2005;54:631-7.
86 Ozdemir D, Tugyan K, Uysal N, Sonmez U, Sonmez A, Acikgoz O, et al. Protective effect of melatonin against head trauma-induced hippocampal damage and spatial memory deficits in immature rats. Neuroscience Letters. 2005;385:234-239.   DOI
87 Fischer TW, Kleszczynski K, Hardkop LH, Kruse N, Zillikens D. Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR-induced depletion, and protects against the formation of DNA damage (8-hydroxy-2'-deoxyguanosine) in ex vivo human skin. Journal of Pineal Research. 2013;54:303-312.   DOI
88 Chung E, Kong X, Goldberg MP, Stowe AM, Raman L. Erythropoietin-mediated neuroprotection in a pediatric mouse model of chronic hypoxia. Neurosci Lett. 2015;597:54-9.   DOI
89 Jelkmann W. Physiology and Pharmacology of Erythropoietin. Transfusion Medicine and Hemotherapy. 2013;40:302-309.   DOI
90 Jurado Garcia JM, Torres Sanchez E, Olmos Hidalgo D, Alba Conejo E. Erythropoietin pharmacology. Clin Transl Oncol. 2007;9:715-22.   DOI
91 Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A, et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A. 2002;99:5627-31.   DOI
92 Dabbagh OC, Aldawood AS, Arabi YM, Lone NA, Brits R, Pillay M. Magnesium supplementation and the potential association with mortality rates among critically ill non-cardiac patients. Saudi Med J. 2006;27:821-5.
93 Riordan WP, Cotton BA, Norris PR, Waitman LR, Jenkins JM, Morris JA. $\beta$-Blocker Exposure in Patients With Severe Traumatic Brain Injury (TBI) and Cardiac Uncoupling. The Journal of Trauma: Injury, Infection, and Critical Care. 2007;63:503-511.   DOI
94 Inaba K, Teixeira PGR, David J-S, Chan LS, Salim A, Brown C, et al. Beta-Blockers in Isolated Blunt Head Injury. Journal of the American College of Surgeons. 2008;206:432-438.   DOI
95 Hadjizacharia P, O'Keeffe T, Brown CV, Inaba K, Salim A, Chan LS, et al. Incidence, risk factors, and outcomes for atrial arrhythmias in trauma patients. Am Surg. 2011;77:634-9.
96 Habgood MD, Bye N, Dziegielewska KM, Ek CJ, Lane MA, Potter A, et al. Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur J Neurosci. 2007;25:231-8.   DOI
97 Koch SM, Warters RD, Mehlhorn U. The simultaneous measurement of ionized and total calcium and ionized and total magnesium in intensive care unit patients. J Crit Care. 2002;17:203-5.   DOI
98 Mirrahimi B, Mortazavi A, Nouri M, Ketabchi E, Amirjamshidi A, Ashouri A, et al. Effect of magnesium on functional outcome and paraclinical parameters of patients undergoing supratentorial craniotomy for brain tumors: a randomized controlled trial. Acta Neurochir (Wien). 2015;157:985-91;discussion 991.   DOI
99 James ML, Blessing R, Phillips-Bute BG, Bennett E, Laskowitz DT. S100B and brain natriuretic peptide predict functional neurological outcome after intracerebral haemorrhage. Biomarkers. 2009;14:388-94.   DOI
100 Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease; 2013.
101 Banach M, Serban C, Sahebkar A, Mikhailidis DP, Ursoniu S, Ray KK, et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. 2015;13:229.   DOI
102 Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005;366:1267-78.   DOI
103 Cotton BA, Snodgrass KB, Fleming SB, Carpenter RO, Kemp CD, Arbogast PG, et al. Beta-Blocker Exposure is Associated With Improved Survival After Severe Traumatic Brain Injury. The Journal of Trauma: Injury, Infection, and Critical Care. 2007;62:26-35.   DOI
104 Chakraborti AK, Garg SK, Kumar R, Motiwala HF, Jadhavar PS. Progress in COX-2 inhibitors: a journey so far. Curr Med Chem. 2010;17:1563-93.   DOI
105 Manabe Y, Anrather J, Kawano T, Niwa K, Zhou P, Ross ME, et al. Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Annals of Neurology. 2004;55:668-675.   DOI
106 Stark DT, Bazan NG. Synaptic and extrasynaptic NMDA receptors differentially modulate neuronal cyclooxygenase-2 function, lipid peroxidation, and neuroprotection. J Neurosci. 2011;31:13710-21.   DOI
107 Capone ML, Tacconelli S, Sciulli MG, Patrignani P. Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol. 2003;16:49-58.   DOI
108 Alderson P, Roberts I. Corticosteroids in acute traumatic brain injury: systematic review of randomised controlled trials. BMJ. 1997;314:1855-9.   DOI
109 Yang Z, Zhao T, Zou Y, Zhang JH, Feng H. Curcumin inhibits microglia inflammation and confers neuroprotection in intracerebral hemorrhage. Immunology Letters. 2014;160:89-95.   DOI
110 Arai K, Wu J, Li Q, Wang X, Yu S, Li L, et al. Neuroprotection by Curcumin in Ischemic Brain Injury Involves the Akt/Nrf2 Pathway. PLoS ONE. 2013;8:e59843.   DOI
111 Sandercock PAG, Soane T, Sandercock PAG. Corticosteroids for acute ischaemic stroke; 2011.
112 Roberts I, Sydenham E, Roberts I. Barbiturates for acute traumatic brain injury; 2012.
113 Bell JD. In Vogue: Ketamine for Neuroprotection in Acute Neurologic Injury. Anesthesia & Analgesia. 2017;1.
114 Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002;70:133-9.   DOI
115 Hurtado O, Hernandez-Jimenez M, Zarruk JG, Cuartero MI, Ballesteros I, Camarero G, et al. Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke. J Neurochem. 2013;126:819-26.   DOI
116 Subiros N, Perez-Saad H, Aldana L, Gibson CL, Borgnakke WS, Garcia-del-Barco D. Neuroprotective effect of epidermal growth factor plus growth hormone-releasing peptide-6 resembles hypothermia in experimental stroke. Neurological Research. 2016;38:950-958.   DOI
117 Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the bloodbrain barrier to protect against experimental brain injury. Proceedings of the National Academy of Sciences. 2000;97:10526-10531.   DOI
118 Chen G, Zhang S, Shi J, Ai J, Hang C. Effects of recombinant human erythropoietin (rhEPO) on JAK2/STAT3 pathway and endothelial apoptosis in the rabbit basilar artery after subarachnoid hemorrhage. Cytokine. 2009;45:162-168.   DOI
119 Sanchez PE, Fares RP, Risso JJ, Bonnet C, Bouvard S, Le-Cavorsin M, et al. Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci U S A. 2009;106:9848-53.   DOI
120 Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, et al. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proceedings of the National Academy of Sciences. 2008;105:6185-6190.   DOI
121 Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005;6:484-94.   DOI
122 Sepulveda P, Encabo A, Carbonell-Uberos F, Minana MD. BCL-2 expression is mainly regulated by JAK/STAT3 pathway in human CD34+ hematopoietic cells. Cell Death and Differentiation. 2006;14:378-380.
123 Ding J, Wang J, Li QY, Yu JZ, Ma CG, Wang X, et al. Neuroprotection and CD131/GDNF/AKT Pathway of Carbamylated Erythropoietin in Hypoxic Neurons. Mol Neurobiol; 2016.
124 Chen J, Chen J, Yang Z, Zhang X. Carbamylated Erythropoietin: A Prospective Drug Candidate for Neuroprotection. Biochemistry Insights. 2016;25.
125 Vinukonda G, Csiszar A, Hu F, Dummula K, Pandey NK, Zia MT, et al. Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition. Brain. 2010;133:2264-2280.   DOI
126 Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem. 2002;9:1033-43.   DOI
127 Singh DP, Chopra K. Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits neuroprotection in rat model of ischaemic stroke. Pharmacol Biochem Behav. 2014;120:33-42.   DOI
128 Ahmad M, Zhang Y, Liu H, Rose ME, Graham SH. Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. Brain Research. 2009;1279:168-173.   DOI
129 Alzheimer C, Werner S. Fibroblast growth factors and neuroprotection. Adv Exp Med Biol. 2002;513:335-51.
130 Sofroniew MV, Howe CL, Mobley WC. Nerve Growth Factor Signaling, Neuroprotection, and Neural Repair. Annual Review of Neuroscience. 2001;24:1217-1281.   DOI
131 Jain KK. The handbook of neuroprotection. Humana: New York; 2011.
132 Porter D, Johnston AM, Henning J. Medical Conditions Requiring Intensive Care. Journal of the Royal Army Medical Corps. 2009;155:141-146.   DOI
133 Peisker T, Koznar B, Stetkarova I, Widimsky P. Acute stroke therapy: A review. Trends in Cardiovascular Medicine. 2017;27:59-66.   DOI
134 Tahir R, Pabaney A. Therapeutic hypothermia and ischemic stroke: A literature review. Surgical Neurology International. 2016;7:381.   DOI
135 Gonzalez-Ibarra FP, Varon J, Lopez-Meza EG. Therapeutic hypothermia: critical review of the molecular mechanisms of action. Frontiers in Neurology. 2011;2:4.
136 Great Britain. Department of Health. Comprehensive critical care: a review of adult critical care services. Department of Health: London 2000.
137 Clausen F, Marklund N, Lewen A, Hillered L. The nitrone free radical scavenger NXY-059 is neuroprotective when administered after traumatic brain injury in the rat. J Neurotrauma. 2008;25:1449-57.   DOI
138 Bianconi V, Sahebkar A, Banach M, Pirro M. Statins, haemostatic factors and thrombotic risk. Curr Opin Cardiol; 2017.
139 Chrusciel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, et al. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194-208.   DOI
140 Derosa G, Maffioli P, Reiner Z, Simental-Mendia LE, Sahebkar A. Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. Drugs. 2016;76:947-56.   DOI
141 Parrillo JE, Dellinger RP. Critical care medicine: principles of diagnosis and management in the adult. Elsevier Mosby: St. Louis, Mo.; London 2008.
142 Chong J, Dumont T, Francis-Frank L, Balaan M. Sepsis and Septic Shock. Critical Care Nursing Quarterly. 2015;38:111-120.   DOI
143 Kavalipati N, Shah J, Ramakrishan A, Vasnawala H. Pleiotropic effects of statins. Indian J Endocrinol Metab. 2015;19:554-62.   DOI
144 Kwon TH, Chao DL, Malloy K, Sun D, Alessandri B, Bullock MR. Tempol, a novel stable nitroxide, reduces brain damage and free radical production, after acute subdural hematoma in the rat. J Neurotrauma. 2003;20:337-45.   DOI
145 Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. Autoimmun Rev. 2016;15:344-53.   DOI
146 Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GY, et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016;115:520-32.   DOI
147 Sahebkar A, Rathouska J, Simental-Mendia LE, Nachtigal P. Statin therapy and plasma cortisol concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2016;103:17-25.   DOI
148 Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res. 2015;60:50-73.   DOI
149 Sahebkar A. Curcumin: A Natural Multitarget Treatment for Pancreatic Cancer. Integrative Cancer Therapies. 2016;15:333-334.   DOI
150 Huang S, Beevers CS. Pharmacological and clinical properties of curcumin. Botanics: Targets and Therapy. 2011;5.
151 Mullaicharam AR, Maheswaran A. Pharmacological effects of curcumin. International journal of Nutrition, Pharmacology, Neurological Diseases. 2012;2:92.   DOI
152 Ghandadi M, Sahebkar A. Curcumin: An effective inhibitor of interleukin-6. Curr Pharm Des; 2016.
153 Aydin MV, Caner H, Sen O, Ozen O, Atalay B, Cekinmez M, et al. Effect of melatonin on cerebral vasospasm following experimental subarachnoid hemorrhage. Neurological Research. 2013;27:77-82.
154 Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for Minocycline Neuroprotection. Archives of Neurology. 2010;67.
155 Amiri-Nikpour MR, Nazarbaghi S, Hamdi-Holasou M, Rezaei Y. An open-label evaluator-blinded clinical study of minocycline neuroprotection in ischemic stroke: gender-dependent effect. Acta Neurologica Scandinavica. 2015;131:45-50.   DOI
156 Wakai A, McCabe A, Roberts I, Schierhout G, Wakai A. Mannitol for acute traumatic brain injury; 2013.
157 Ayer RE, Sugawara T, Chen W, Tong W, Zhang JH. Melatonin decreases mortality following severe subarachnoid hemorrhage. Journal of Pineal Research. 2008;44:197-204.   DOI
158 Zausinger S, Westermaier T, Plesnila N, Steiger HJ, Schmid-Elsaesser R. Neuroprotection in Transient Focal Cerebral Ischemia by Combination Drug Therapy and Mild Hypothermia: Comparison With Customary Therapeutic Regimen. Stroke. 2003;34:1526-1532.   DOI
159 Rak R, Chao DL, Pluta RM, Mitchell JB, Oldfield EH, Watson JC. Neuroprotection by the stable nitroxide Tempol during reperfusion in a rat model of transient focal ischemia. J Neurosurg. 2000;92:646-51.   DOI
160 Kato N, Yanaka K, Hyodo K, Homma K, Nagase S, Nose T. Stable nitroxide Tempol ameliorates brain injury by inhibiting lipid peroxidation in a rat model of transient focal cerebral ischemia. Brain Res. 2003;979:188-93.   DOI
161 Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener H-C, et al. NXY-059 for Acute Ischemic Stroke. New England Journal of Medicine. 2006;354:588-600.   DOI
162 Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the Treatment of Acute Ischemic Stroke. New England Journal of Medicine. 2007;357:562-571.   DOI
163 Lorenz P, Roychowdhury S, Engelmann M, Wolf G, Horn TF. Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: effect on nitrosative and oxidative stress derived from microglial cells. Nitric Oxide. 2003;9:64-76.   DOI
164 Maples KR, Ma F, Zhang YK. Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059. Free Radic Res. 2001;34:417-26.   DOI
165 Strid S, Borga O, Edenius C, Jostell KG, Odergren T, Weil A. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. Eur J Clin Pharmacol. 2002;58:409-15.   DOI
166 Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem. 2012;49:580-8.   DOI
167 Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental-Mendia LE, Majeed M, et al. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomed Pharmacother. 2016;82:578-82.   DOI
168 Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clin Nutr. 2015;34:1101-8.   DOI
169 Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res. 2014;28:633-42.   DOI
170 Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M, et al. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Inflammopharmacology. 2017;25:25-31.   DOI
171 Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. Journal of the American Medical Association. 2009;302:2323-9.   DOI
172 Gora-Kupilas K, Josko J. The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol. 2005;43:31-9.
173 Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign Guidelines Committee including The Pediatric S. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Medicine. 2013;39:165-228.   DOI
174 Angus DC, van der Poll T. Severe Sepsis and Septic Shock. New England Journal of Medicine. 2013;369:840-851.   DOI
175 Mock C, Lormand JD, Goosen J, Joshipura M, Peden M. Guidelines for essential trauma care. Geneva : World Health Organization; 2004.
176 Shen Q, Hiebert JB, Hartwell J, Thimmesch AR, Pierce JD. Systematic Review of Traumatic Brain Injury and the Impact of Antioxidant Therapy on Clinical Outcomes. Worldviews on Evidence-Based Nursing. 2016;13:380-389.   DOI
177 Gruenbaum SE, Zlotnik A, Gruenbaum BF, Hersey D, Bilotta F. Pharmacologic Neuroprotection for Functional Outcomes After Traumatic Brain Injury: A Systematic Review of the Clinical Literature. CNS Drugs. 2016;30:791-806.   DOI
178 Sahebkar A, Ponziani MC, Goitre I, Bo S. Does statin therapy reduce plasma VEGF levels in humans? A systematic review and meta-analysis of randomized controlled trials. Metabolism. 2015;64:1466-76.   DOI
179 Sahebkar A, Kotani K, Serban C, Ursoniu S, Mikhailidis DP, Jones SR, et al. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis. 2015;241:433-42.   DOI
180 Serban C, Sahebkar A, Ursoniu S, Mikhailidis DP, Rizzo M, Lip GY, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep. 2015;5:9902.   DOI
181 Park E, Bell JD, Baker AJ. Traumatic brain injury: Can the consequences be stopped? Canadian Medical Association Journal. 2008;178:1163-1170.   DOI
182 Tromp G, Weinsheimer S, Ronkainen A, Kuivaniemi H. Molecular basis and genetic predisposition to intracranial aneurysm. Annals of Medicine. 2014;46:597-606.   DOI
183 Wills S, Ronkainen A, van der Voet M, Kuivaniemi H, Helin K, Leinonen E, et al. Familial intracranial aneurysms: an analysis of 346 multiplex Finnish families. Stroke. 2003;34:1370-4.   DOI
184 Simental-Mendia LE, Sahebkar A, Rodriguez-Moran M, Guerrero-Romero F. A systematic review and meta-analysis of randomized controlled trials on the effects of magnesium supplementation on insulin sensitivity and glucose control. Pharmacological Research. 2016;111:272-82.   DOI
185 Fugere M, Appel J, Houghten RA, Lindberg I, Day R. Short Polybasic Peptide Sequences Are Potent Inhibitors of PC5/6 and PC7: Use of Positional Scanning-Synthetic Peptide Combinatorial Libraries as a Tool for the Optimization of Inhibitory Sequences. Molecular Pharmacology. 2006;71:323-332.   DOI
186 Akhtar MI, Ullah H, Hamid M. Magnesium, a drug of diverse use. Journal of Pakistan Medical Association. 2011;61:1220-5.
187 Zhang X, Li Y, Del Gobbo LC, Rosanoff A, Wang J, Zhang W, Song Y. Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials. Hypertension. 2016;68:324-33.   DOI
188 Sharma P, Chung C, Vizcaychipi M. Magnesium: The Neglected Electrolyte? A Clinical Review. Pharmacology & Pharmacy. 2014;05:762-772.   DOI
189 McIntosh TK, Juhler M, Wieloch T. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: 1998. Journal of Neurotrauma. 1998;15:731-69.   DOI
190 Memon ZI, Altura BT, Benjamin JL, Cracco RQ, Altura BM. Predictive value of serum ionized but not total magnesium levels in head injuries. Scandinavian Journal of Clinical and Laboratory Investigation. 1995;55:671-7.   DOI
191 Afshari D, Moradian N, Rezaei M. Evaluation of the intravenous magnesium sulfate effect in clinical improvement of patients with acute ischemic stroke. Clinical Neurology and Neurosurgery. 2013;115:400-4.   DOI
192 Asahi M, Huang Z, Thomas S, Yoshimura S, Sumii T, Mori T, et al. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab. 2005;25:722-9.   DOI
193 Sahebkar A, Serban C, Mikhailidis DP, Undas A, Lip GYH, Muntner P, et al. Association between statin use and plasma d-dimer levels: A systematic review and meta-analysis of randomised controlled trials. Thrombosis and Haemostasis. 2015;114:546-557.   DOI
194 Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3-11.   DOI
195 Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-10.   DOI
196 Jain MK, Ridker PM. Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. Nature Reviews Drug Discovery. 2005;4:977-987.   DOI
197 Moon GJ, Kim SJ, Cho YH, Ryoo S, Bang OY. Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J Clin Neurol. 2014;10:140-7.   DOI
198 Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of Systemic Oxidative Stress by Curcuminoids in Osteoarthritis: Results of a Randomized Controlled Trial. J Diet Suppl. 2016;13:209-20.   DOI
199 Panahi Y, Ghanei M, Hajhashemi A, Sahebkar A. Effects of Curcuminoids-Piperine Combination on Systemic Oxidative Stress, Clinical Symptoms and Quality of Life in Subjects with Chronic Pulmonary Complications Due to Sulfur Mustard: A Randomized Controlled Trial. J Diet Suppl. 2016;13:93-105.   DOI
200 Uchino H, Minamikawa-Tachino R, Kristian T, Perkins G, Narazaki M, Siesjo BK, et al. Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition. Neurobiol Dis. 2002;10:219-33.   DOI
201 Arii T, Kamiya T, Arii K, Ueda M, Nito C, Katsura K-I, et al. Neuroprotective effect of immunosuppressant FK506 in transient focal ischemia in rats: Therapeutic time window for FK506 in transient focal ischemia. Neurological Research. 2013;23:755-760.
202 Saganova K, Galik J, Blasko J, Korimova A, Racekova E, Vanicky I. Immunosuppressant FK506: Focusing on neuroprotective effects following brain and spinal cord injury. Life Sciences. 2012;91:77-82.   DOI
203 Sharifi Z-N, Abolhassani F, Zarrindast MR, Movassaghi S, Rahimian N, Hassanzadeh G. Effects of FK506 on Hippocampal CA1 Cells Following Transient Global Ischemia/Reperfusion in Wistar Rat. Stroke Research and Treatment. 2012;2012:1-8.
204 Zawadzka M, Kaminska B. A novel mechanism of FK506-mediated neuroprotection: Downregulation of cytokine expression in glial cells. Glia. 2005;49:36-51.   DOI
205 Pillans P. Experimental and Clinical Pharmacology: Immunosuppressants - mechanisms of action and monitoring. Australian Prescriber. 2006;29:99-101.   DOI
206 Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715-29.   DOI
207 Szydlowska K, Gozdz A, Dabrowski M, Zawadzka M, Kaminska B. Prolonged activation of ERK triggers glutamate-induced apoptosis of astrocytes: neuroprotective effect of FK506. Journal of Neurochemistry. 2010;113:904-918.   DOI
208 Abdollahi E, Momtazi AA, Johnston TP, Sahebkar A. Therapeutic Effects of Curcumin in Inflammatory and Immune-Mediated Diseases: A Nature-Made Jack-of-All-Trades? J Cell Physiol; 2017.
209 Sahebkar A, Mohammadi A, Atabati A, Rahiman S, Tavallaie S, Iranshahi M, et al. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res. 2013;27:1883-8.   DOI
210 Panahi Y, Sahebkar A, Amiri M, Davoudi SM, Beiraghdar F, Hoseininejad SL, et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2012;108:1272-9.   DOI
211 Karimian MS, Pirro M, Majeed M, Sahebkar A. Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev; 2016.
212 Derosa G, Maffioli P, Simental-Mendia LE, Bo S, Sahebkar A. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016;111:394-404.   DOI
213 Sahebkar A, Cicero AF, Simental-Mendia LE, Aggarwal BB, Gupta SC. Curcumin downregulates human tumor necrosis factor-alpha levels: A systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res. 2016;107:234-42.   DOI
214 Graham SH, Chen J. Programmed Cell Death in Cerebral Ischemia. Journal of Cerebral Blood Flow & Metabolism. 2001;99-109.
215 Guo Y, Li P, Guo Q, Shang K, Yan D, Du S, et al. Pathophysiology and Biomarkers in Acute Ischemic Stroke - A Review. Tropical Journal of Pharmaceutical Research. 2014;12:1097.   DOI
216 Liou AKF, Clark RS, Henshall DC, Yin XM, Chen J. To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: a review on the stress-activated signaling pathways and apoptotic pathways. Progress in Neurobiology. 2003;69:103-142.   DOI
217 Elmore S. Apoptosis: A Review of Programmed Cell Death. Toxicologic Pathology. 2007;35:495-516.   DOI
218 Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacologica Sinica. 2009;30:379-387.   DOI
219 Parizadeh SMR, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S, et al. Simvastatin therapy reduces prooxidant-antioxidant balance: Results of a placebo-controlled cross-over trial. Lipids. 2011;46:333-340.   DOI
220 Muramoto M, Yamazaki T, Nishimura S, Kita Y. Detailed in vitro pharmacological analysis of FK506-induced neuroprotection. Neuropharmacology. 2003;45:394-403.   DOI
221 Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Molecular Neurobiology. 2003;27:325-55.   DOI
222 Sims NR, Zaidan E. Biochemical changes associated with selective neuronal death following short-term cerebral ischaemia. International Journal of Biochemistry & Cell Biology. 1995;27:531-50.   DOI
223 Ndountse LT, Chan HM. Role of N-methyl-D-aspartate receptors in polychlorinated biphenyl mediated neurotoxicity. Toxicology Letters. 2009;184:50-5.   DOI
224 Wong PC, Cai H, Borchelt DR, Price DL. Genetically engineered mouse models of neurodegenerative diseases. Nature Neuroscience. 2002;5:633-9.   DOI
225 Parathath SR, Parathath S, Tsirka SE. Nitric oxide mediates neurodegeneration and breakdown of the bloodbrain barrier in tPA-dependent excitotoxic injury in mice. Journal of Cell Science. 2006;119:339-49.   DOI